| Bioactivity | Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma[1][2][3]. |
| Invitro | Drozitumab selectively eliminates cancer stem cells (CSCs), resulting in tumor growth inhibition and even regression of pancreatic tumors[3].Drozitumab induces apoptosis in mesenchymal TNBC cell lines but not in cell lines from other breast cancer subtypes[1]. |
| Name | Drozitumab |
| CAS | 912628-39-8 |
| Molar Mass | 143.1 (kDa) |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dine JL, et al. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat. 2016 Jan;155(2):235-51. [2]. Kang Z, et al. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res. 2011 May 15;17(10):3181-92. [3]. Eng JW, et al. Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. J Immunother Cancer. 2016 Jun 21;4:33. |